We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NNOX:NASDAQNANO-X IMAGING LTD Analysis

Data as of 2026-09-02 - not real-time

$0.79

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Nano-X Imaging Ltd. is priced at $0.7859 and its moving averages line up in bearish order, the shorter trailing the longer. It has lost 27.2% over the past 30 days. Momentum indicators put RSI at 32.2 (approaching oversold) with MACD reading bearish. The recent range runs from support at $0.7750 up to resistance at $1.13.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 553.2% above the current quote. Revenue is growing at 53.1%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 77.9%, a beta of 1.71 and a maximum drawdown of 82.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.

Top Market Events

NNOX EQUITY ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nano-X Imaging NNOX Investors of Securities Class Action...Nano-X Imaging Ltd. Stockholders Who Suffered Significant Losses Should Contact Robbins LLP Before the August 11 Lead...Investornewsbreaks NANO-X IMAGING LTD NASDAQ: NNOX Announces $8 Million Registered Direct Offering.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 2.17
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 2.17
  • Analyst targets imply +553.2% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +553.2% versus the current price
  • Negative return on equity of -50.1%
  • Revenue growth of +53.1%

Key Metrics & Analysis

Financial Health

Revenue Growth53.10%
P/E Ratio-2.6
ROE-50.12%
ROA-22.29%
Debt/Equity6.05
P/B Ratio0.4
Op. Cash Flow$-44420000
Free Cash Flow$-28922250
Industry P/E30.6

Technical Analysis

TrendBearish
RSI32.2
Support$0.77
Resistance$1.13
MA 20$0.93
MA 50$1.04
MA 200$2.17
MACDBearish
VolumeDecreasing
Fear & Greed Index92.68

Valuation

Target Price$5.13
Upside/Downside553.18%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.71
Volatility77.87%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.